Document is current
Any future updates will be listed below
-
Authors
Jarzab, Anna https://orcid.org/0000-0002-1059-9147
Kurzawa, Nils https://orcid.org/0000-0002-7846-2817
Hopf, Thomas
Moerch, Matthias
Zecha, Jana https://orcid.org/0000-0002-8767-6294
Leijten, Niels https://orcid.org/0000-0002-7305-7249
Bian, Yangyang
Musiol, Eva
Maschberger, Melanie
Stoehr, Gabriele
Becher, Isabelle https://orcid.org/0000-0001-7170-2235
Daly, Charlotte
Samaras, Patroklos https://orcid.org/0000-0001-6042-1585
Mergner, Julia
Spanier, Britta
Angelov, Angel https://orcid.org/0000-0002-9228-0817
Werner, Thilo
Bantscheff, Marcus https://orcid.org/0000-0002-8343-8977
Wilhelm, Mathias https://orcid.org/0000-0002-9224-3258
Klingenspor, Martin
Lemeer, Simone https://orcid.org/0000-0002-6230-9471
Liebl, Wolfgang
Hahne, Hannes https://orcid.org/0000-0003-3601-0051
Savitski, Mikhail M. https://orcid.org/0000-0003-2011-9247
Kuster, Bernhard https://orcid.org/0000-0002-9094-1677
- License Information
-
More Information
Article History
Received: 2 July 2019
Accepted: 12 March 2020
First Online: 13 April 2020
Competing interests
: H.H. is cofounder, shareholder and CEO of OmicScouts GmbH. M.W. and B.K. are cofounders and shareholders of OmicScouts GmbH and msAId GmbH. M.W. and B.K. have no operational role in either company. T.W. and M.B. are employees and shareholders of GlaxoSmithKline. M.M.S. is a shareholder of GlaxoSmithKline.
